These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 19113918

  • 21. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB, Geusens P, Barton IP, Felsenberg D.
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [Abstract] [Full Text] [Related]

  • 22. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C.
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [Abstract] [Full Text] [Related]

  • 23. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [Abstract] [Full Text] [Related]

  • 24. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 26. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [Abstract] [Full Text] [Related]

  • 27. COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss.
    MacDonald HM, McGuigan FA, New SA, Campbell MK, Golden MH, Ralston SH, Reid DM.
    J Bone Miner Res; 2001 Sep; 16(9):1634-41. PubMed ID: 11547832
    [Abstract] [Full Text] [Related]

  • 28. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.
    Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM, FLEX Research Group.
    J Bone Miner Res; 2010 May; 25(5):976-82. PubMed ID: 20200926
    [Abstract] [Full Text] [Related]

  • 30. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation.
    Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP.
    J Bone Miner Res; 1999 Mar; 14(3):342-50. PubMed ID: 10027899
    [Abstract] [Full Text] [Related]

  • 31. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.
    Zhang G, Qin L, Shi Y.
    J Bone Miner Res; 2007 Jul; 22(7):1072-9. PubMed ID: 17419678
    [Abstract] [Full Text] [Related]

  • 32. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D.
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [Abstract] [Full Text] [Related]

  • 33. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study.
    Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC.
    J Bone Miner Res; 2010 Mar; 25(3):472-81. PubMed ID: 19778182
    [Abstract] [Full Text] [Related]

  • 34. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, Fracture Intervention Trial Study Group.
    J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [Abstract] [Full Text] [Related]

  • 36. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
    Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A.
    Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
    [Abstract] [Full Text] [Related]

  • 37. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
    Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators.
    J Bone Miner Res; 2008 Oct; 23(10):1591-600. PubMed ID: 18505369
    [Abstract] [Full Text] [Related]

  • 38. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 39. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
    Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ.
    Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318
    [Abstract] [Full Text] [Related]

  • 40. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
    Eastell R, Krege JH, Chen P, Glass EV, Reginster JY.
    Curr Med Res Opin; 2006 Jan; 22(1):61-6. PubMed ID: 16393431
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.